全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Comparison of Mortality, Length of Stay, and Hospitalization Costs of Hospitalized COVID-19 Patients with Cardiac and Non-Cardiac Disease

DOI: 10.4236/ojem.2023.113007, PP. 57-67

Keywords: COVID-19, Cardiac Disease, Length of Hospital Stay, Costs, Mortality

Full-Text   Cite this paper   Add to My Lib

Abstract:

Background: The COVID-19 pandemic has presented unprecedented challenges to global healthcare systems. As the pandemic unfolded, it became evident that certain groups of individuals were at an elevated risk of experiencing severe disease outcomes. Among these high-risk groups, individuals with pre-existing cardiac conditions emerged as particularly vulnerable. Objective: This study aimed to investigate the relationship between the length of stay, mortality, and costs of COVID-19 patients with and without a history of cardiac disease. Design: This retrospective study was conducted in Jam Hospital in Tehran, Iran, from March 21, 2021, to March 21, 2022. All patients with laboratory-confirmed COVID-19 who were hospitalized during this period were included. Results: A total of 500 COVID-19 patients were hospitalized, with 31.6% having a history of cardiac disease and 68.4% without any cardiac disease. Patients with cardiac disease were significantly older (median [range] age, 69.35 [37 - 94] years) compared to non-cardiac patients (54.95 [13 - 97] years) (p < 0.001). Hypertension (39.2%) and diabetes (28.6%) were the most prevalent comorbid conditions. According to the Cox regression model, patients with cardiac disease did not have a statistically higher risk of death than those without cardiac disease. However, age and underlying disease were significant risk factors for mortality with COVID-19, with high hazard ratios (HRs) of 1.041 (95% CI, 1.041 - 1.070) and 2.297 (95% CI, 1.152 - 4.581), respectively. The median length of stay (LOS) in cardiac patients was seven days, with an average total cost of $1865.77 per patient, significantly higher than in patients with no cardiac history (p-value: 0.004, <0.001). Conclusion: Patients with cardiac disease who are hospitalized with COVID-19 have a higher mortality rate, longer hospital stays, greater disease severity, ICU admission, and higher costs. Therefore, improved prevention and management strategies are crucial for these patients.

References

[1]  Ciotti, M., Ciccozzi, M., Terrinoni, A., Jiang, W.C., Wang, C.B. and Bernardini, S. (2020) The COVID-19 Pandemic. Critical Reviews in Clinical Laboratory Sciences, 57, 365-388.
https://doi.org/10.1080/10408363.2020.1783198
[2]  Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., et al. (2020) Clinical Features of Patients Infected with 2019 Novel Coronavirus in Wuhan, China. The Lancet, 395, 497-506.
https://doi.org/10.1016/S0140-6736(20)30183-5
[3]  Yang, J., Zheng, Y., Gou, X., Pu, K., Chen, Z., Guo, Q., et al. (2020) Prevalence of Comorbidities and Its Effects in Patients Infected with SARS-CoV-2: A Systematic Review and Meta-Analysis. International Journal of Infectious Diseases, 94, 91-95.
https://doi.org/10.1016/j.ijid.2020.03.017
[4]  Alsaied, T., Aboulhosn, J.A., Cotts, T.B., Daniels, C.J., Etheridge, S.P., Feltes, T.F., et al. (2020) Coronavirus Disease 2019 (COVID-19) Pandemic Implications in Pediatric and Adult Congenital Heart Disease. Journal of the American Heart Association, 9, e017224.
https://doi.org/10.1161/JAHA.120.017224
[5]  Guan, W.J., Ni, Z.Y., Hu, Y., Liang, W.H., Ou, C.Q., He, J.X., et al. (2020) Clinical Characteristics of 2019 Novel Coronavirus Infection in China. The New England Journal of Medicine, 382, 1708-1720.
https://doi.org/10.1056/NEJMoa2002032
[6]  Kliff, S. (2020) Hospitals Knew How to Make Money. Then Coronavirus Happened. The New York Times.
[7]  Gupta, A., Madhavan, M.V., Sehgal, K., Nair, N., Mahajan, S., Sehrawat, T.S., et al. (2020) Extrapulmonary Manifestations of COVID-19. Nature Medicine, 26, 1017-1032.
https://doi.org/10.1038/s41591-020-0968-3
[8]  Azari, S., Omidi, N., Arabloo, J., Pourhosseini, H. and Rezapour, A. (2020) Resource Utilization and Cost of Hospitalized Patients with COVID-19 in Iran: Rationale and Design of a Protocol. Frontiers in Emergency Medicine, 4, e55.
[9]  Bonow, R.O., Fonarow, G.C., O’Gara, P.T. and Yancy, C.W. (2020) Association of Coronavirus Disease 2019 (COVID-19) with Myocardial Injury and Mortality. JAMA Cardiology, 5, 751-753.
https://doi.org/10.1001/jamacardio.2020.1105
[10]  Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., et al. (2020) Epidemiological and Clinical Characteristics of 99 Cases of 2019 Novel Coronavirus Pneumonia in Wuhan, China: A Descriptive Study. The Lancet, 395, 507-513.
https://doi.org/10.1016/S0140-6736(20)30211-7
[11]  Abadir, S. and Khairy, P. (2011) Electrophysiology and Adult Congenital Heart Disease: Advances and Options. Progress in Cardiovascular Diseases, 53, 281-292.
https://doi.org/10.1016/j.pcad.2010.07.003
[12]  de Almeida-Pititto, B., Dualib, P.M., Zajdenverg, L., Dantas, J.R., De Souza, F.D., Rodacki, M., et al. (2020) Severity and Mortality of COVID 19 in Patients with Diabetes, Hypertension and Cardiovascular Disease: A Meta-Analysis. Diabetology & Metabolic Syndrome, 12, Article No. 75.
https://doi.org/10.1186/s13098-020-00586-4
[13]  Iaccarino, G., Grassi, G., Borghi, C., Ferri, C., Salvetti, M. and Volpe, M. (2020) Age and Multimorbidity Predict Death among COVID-19 Patients: Results of the SARS-RAS Study of the Italian Society of Hypertension. Hypertension, 76, 366-372.
https://doi.org/10.1161/HYPERTENSIONAHA.120.15324
[14]  Porcheddu, R., Serra, C., Kelvin, D., Kelvin, N. and Rubino, S. (2020) Similarity in Case Fatality Rates (CFR) of COVID-19/SARS-COV-2 in Italy and China. The Journal of Infection in Developing Countries, 14, 125-128.
https://doi.org/10.3855/jidc.12600
[15]  Wu, Z. and McGoogan, J.M. (2020) Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases from the Chinese Center for Disease Control and Prevention. Journal of the American Medical Association, 323, 1239-1242.
https://doi.org/10.1001/jama.2020.2648
[16]  Lui, G.K., Saidi, A., Bhatt, A.B., Burchill, L.J., Deen, J.F., Earing, M.G., et al. (2017) Diagnosis and Management of Noncardiac Complications in Adults with Congenital Heart Disease: A Scientific Statement from the American Heart Association. Circulation, 136, e348-e392.
https://doi.org/10.1161/CIR.0000000000000535
[17]  Bare, I., Crawford, J., Pon, K., Farida, N. and Dehghani, P. (2018) Frequency and Consequences of Influenza Vaccination in Adults with Congenital Heart Disease. The American Journal of Cardiology, 121, 491-494.
https://doi.org/10.1016/j.amjcard.2017.11.008
[18]  Clerkin, K.J., Fried, J.A., Raikhelkar, J., Sayer, G., Griffin, J.M., Masoumi, A., et al. (2020) COVID-19 and Cardiovascular Disease. Circulation, 141, 1648-1655.
https://doi.org/10.1161/CIRCULATIONAHA.120.046941

Full-Text

Contact Us

[email protected]

QQ:3279437679

WhatsApp +8615387084133